Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk
These Lynparza website pages were funded and produced by AstraZeneca UK and MSD UK
Homologous recombination deficiency is common in ovarian cancer. Approximately 1-in-2 women with advanced ovarian cancer have HRD-positive tumours (including those with a tBRCAm).3-5
HRD testing can provide crucial diagnostic information to guide personalised treatment options for patients with newly diagnosed aOC:1,6
Homologous recombination deficiency (HRD) is the impaired ability of a cell to accurately repair DNA, and is a hallmark of cancer. Lynparza induces cancer cell death by inhibiting PARP, a DNA repair enzyme utilised by HRD tumour cells.7
Note: This data is pre-clinical data and should not be extended to the clinical setting. Pre-clinical data suggests a co-targeting mechanism of PARP inhibitors plus anti-angiogenic agents.8,9
Biomarker testing should be integrated early in the diagnostic pathway, alongside biopsy and histology, to identify BRCA mutations and HRD status. The molecular characteristics of aOC should then be used to direct treatment choices, as recommended by the latest ESMO guidelines.10
All patients with newly diagnosed, advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer are eligible to be tested for HRD.1
Please consult the SmPC for further information before making any prescribing decisions.
GB-73639 | February 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.